The company Novo Nordisk claims that its drug CagriSema could help patients lose a quarter of their weight. Lotte Bjerre Knudsen, a scientific advisor at Novo, notes that while there are many similar compounds on the market, the technologies being developed are more promising. So far, Novo Nordisk and its competitor Eli Lilly & Co. have dominated the obesity treatment market with their products Ozempic, Wegovy, Zepbound, and Mounjaro.
Both pharmaceutical companies are looking to offer more effective medications with fewer side effects. Despite some public figures opposing these drugs, it is expected that by 2027 there will be up to a dozen new obesity medications on the market. Dan Skovronsky, Lilly's chief scientific officer, emphasizes the competition among companies to innovate and improve their offerings.
The rapid advancement in the field of obesity treatments offers a range of possibilities in medicine. Various clinical studies are underway, and a variety of options are expected in the coming years. Leading companies like Novo and Lilly are striving to stay at the forefront and meet market demands, which could reach $50 billion annually.
Knudsen mentions that, with data obtained from ongoing research, new ways to treat obesity-related diseases and diabetes are expected to be discovered. Kazi Helal, a PitchBook analyst, suggests that the market is demanding alternatives to existing treatments. Novo is confident in competing in a growing market, as there is still ample space for innovation and development of more effective treatments.
Meanwhile, Lilly has presented promising results with its injection Retatrutide, which has shown an average weight reduction of 24% in a mid-stage study. The quest to find the most effective treatment for obesity continues, and significant advances in the field of medicine for this disease are expected in the coming years.
